01—Abstract
Summary
Summary of the 10-K filed February 25, 2025. Cited figures are marked; the original filing is the authoritative source.
Fortive Corporation's 2024 Form 10-K reports total sales of $6.23 billiona, up from $6.07 billion in 2023, with operating profit of $1.21 billion and net earnings of $832.9 million, or $2.36 per diluted share, compared with $865.8 million in 2023.
Sales growth of 2.7%b combined 1.3% core revenue growth with a 2.0% contribution from acquisitions, net of divestitures, partially offset by a 0.6% currency decline. Operating profit margin was 19.4%, up 70 basis points. The growth was led by Intelligent Operating Solutions and Advanced Healthcare Solutions, while Precision Technologies core revenue declined 3.7%.
The company completed the $1.72 billionc acquisition of EA Elektro-Automatik in January 2024, which added approximately $1.18 billion of goodwill to the PT segment. The company plans to separate its Precision Technologies segment into an independent public company named Ralliant, targeting completion early in the third quarter of 2025, subject to conditions including board approval, financing, tax opinions or a private letter ruling, and a Form 10 registration statement. The 2025 outlook calls for full-year sales growth between approximately flat and 2.0%.
Cash flow from operations was $1.53 billiond, and the company repurchased 12.0 million shares for $889.6 million in cash during 2024. Total debt was approximately $3.7 billion at year-end, with $813 million of cash and cash equivalents and a $2.0 billion undrawn revolving credit facility. Key risks highlighted include global economic conditions, trade policy and tariffs affecting China, foreign currency exposure (approximately 46% of 2024 sales came from outside the United States), and the tax treatment of the Separation, which could create significant tax liabilities if determined to be taxable.
02—Key points
Key Highlights
- Total sales rose to $6.23 billion in 2024 from $6.07 billion in 2023, up 2.7%, with core revenue up 1.3%.
- Operating profit margin was 19.4% in 2024, up 70 basis points from 18.7% in 2023; gross profit margin was 59.9%.
- Net earnings were $832.9 million, or $2.36 per diluted share, versus $865.8 million, or $2.43 per diluted share, in 2023.
- The EA Elektro-Automatik acquisition, completed January 3, 2024 for approximately $1.72 billion net of acquired cash, added about $1.18 billion of goodwill in the Precision Technologies segment.
- The planned separation of the Precision Technologies segment into a new public company named Ralliant is targeted for completion early in the third quarter of 2025.
- Share repurchases totaled $889.6 million in cash in 2024 (12.0 million shares at an average price of $73.93), and the quarterly dividend was $0.08 per share.
- Total debt was approximately $3.7 billion at December 31, 2024, with $813 million of cash and cash equivalents and $2.0 billion available under the revolving credit facility.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2024, Fortive kept $0.20.
- Revenue$4.08B100.0%
- Cost of revenue−$1.46B35.8%
- Gross profit$2.62B64.2%
- Operating costs−$1.90B46.6%
- Operating income$716.3M17.6%
- Interest, other & tax$116.6M2.9%
- Net income$832.9M20.4%
Where FY2024 revenue went
$4.08B- SG&A: $1.65B, 40% of revenue
- Cost of revenue: $1.46B, 36% of revenue
- Operating income: $716.3M, 18% of revenue
- R&D: $251.3M, 6.2% of revenue
Kept 18% as operating income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2024filed February 25, 2025Financial Statements
FY2024 against FY2023
| Line item | FY2024FY2023 | Change |
|---|---|---|
| Revenue | $4.08B$3.91B | +4.3% |
| Cost of Revenue | $1.46B$1.44B | +1.7% |
| Gross Profit | $2.62B$2.48B | +5.7% |
| R&D Expenses | $251.30M$237.00M | +6.0% |
| SG&A Expenses | $1.65B$1.67B | −0.9% |
| Operating Expenses | -$1.90B-$1.90B | 0.0% |
| Operating Income | $716.30M$574.00M | +24.8% |
| Interest Expense | -$152.80M-$123.50M | −23.7% |
| Net Income | $832.90M$865.80M | −3.8% |
| EPS (Basic) | $2.39$2.46 | −2.8% |
| EPS (Diluted) | $2.36$2.43 | −2.9% |
| Shares Outstanding (Basic) | 349.20M352.50M | −0.9% |
| Shares Outstanding (Diluted) | 352.80M355.60M | −0.8% |
05—Questions
Frequently Asked Questions
What is the outlook for 2025 sales?
Fortive anticipates full-year 2025 sales growth of approximately flat to 2.0%, with year-over-year growth from existing businesses of approximately 1.5% to 3.5%. The company cites foreign exchange volatility, trade policy uncertainty, and macroeconomic conditions in the United States, China and other regions as factors that could affect results.
What is the Ralliant separation and when is it expected?
Fortive plans to separate its Precision Technologies segment into an independent publicly traded company named Ralliant. Fortive will retain the Fortive name and the Intelligent Operating Solutions and Advanced Healthcare Solutions businesses. The company is targeting completion early in the third quarter of 2025, subject to conditions including final board approval, satisfactory financing, a favorable tax opinion or private letter ruling, effectiveness of a Form 10 registration statement, and other regulatory approvals.
How did each segment perform in 2024?
Intelligent Operating Solutions sales rose to $2.71 billion from $2.61 billion, with core revenue growth of 3.4%. Advanced Healthcare Solutions sales rose to $1.29 billion from $1.23 billion, with core revenue growth of 6.1%. Precision Technologies sales were $2.23 billion, essentially flat with the prior year, but core revenue declined 3.7%, offset by the EA acquisition.
What are the main risks to Fortive's international business?
Approximately 46% of 2024 sales were derived from customers outside the United States. The filing highlights risks from trade protection measures and tariffs, particularly regarding China, foreign currency exchange rate volatility, geopolitical conflict, and changes in political or economic conditions. The company does not use derivative financial instruments to manage most currency exposure.
06—Continue